ELCC 2021 - European Lung Cancer Congress (Virtual Meeting)
Mar 25 - Mar 27, 2021 | GenevaSwitzerland
LARVOL is not affiliated with European Lung Cancer Congress (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 44 abstracts linked to Trials
[VIRTUAL] KRYSTAL-1: Activity and Preliminary Pharmacodynamic (PD) Analysis of Adagrasib (MRTX849) in Patients (Pts) With Advanced Non-Small- Cell Lung Cancer (NSCLC) Harboring KRASG12C Mutation
[VIRTUAL] First-Line Pembrolizumab Plus Chemotherapy for Patients With Advanced Squamous NSCLC: 3-Year Follow-up From KEYNOTE-407
[VIRTUAL] Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial
[VIRTUAL] First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA
[VIRTUAL] Phase 1 study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)
[VIRTUAL] Tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC: Efficacy results from all pts enrolled in VISION cohort A
[VIRTUAL] Patterns of relapse following thoracic radiotherapy in patients with limited-stage small cell lung cancer as part of the CONVERT trial
[VIRTUAL] Olaparib maintenance vs placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial
[VIRTUAL] DUART: A phase II study of durvalumab following radiotherapy in patients with unresectable, stage III NSCLC ineligible for chemotherapy
[VIRTUAL] Early safety assessment of durvalumab after sCRT in patients with Stage III, unresectable NSCLC (PACIFIC-6)
[VIRTUAL] PACIFIC-R: real-world characteristics of unresectable Stage III NSCLC patients treated with durvalumab after chemoradiotherapy
[VIRTUAL] A phase Ib study of CC-90011, a potent, reversible, oral LSD1 inhibitor, plus etoposide and cisplatin (EP) or carboplatin (EC) in patients (Pts) with first-line (1L) extensive-stage (ES) small cell lung cancer (SCLC): Updated results
[VIRTUAL] First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW)
[VIRTUAL] First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC)
[VIRTUAL] Real-world outcomes of patients with metastatic non-small cell lung cancer receiving 2L+ atezolizumab-based treatments in Taiwan clinical practice